GXNPC1®

Stroke is the most common cerebrovascular disease, the leading cause of death in Taiwan, and causes varying degrees of disability. Current treatments are limited to passive rehabilitation and do not provide effective solutions. Severe cases that require long-term care place a huge psychological and financial burden on caregivers and families.

GXNPC1® is a ground breaking autologous adipose stem cell therapy designed to treat chronic stroke. Preclinical studies have shown that GXNPC1® can enhance the expression of homing effect, anti-inflammatory response and angiogenesis. In animal models of ischemic stroke, GXNPC1® showed significant improvements in behavioral tests, including balance beam walking, locomotor activity, and rotation analyses.

In Phase I clinical trials, GXNPC1® was found to be safe, with no adverse events reported. Furthermore, all subjects showed significant improvement six months after transplantation, and the infarction areas in the brains of three treated subjects have shrunk (Tsung-Lang Chiu et al., 2022). GXNPC1® has currently completed phase II clinical trials (NCT04088149). In the clinical trial phase II, the high dose cohort (2 x 10^8 cells) through intracerebral injection showed a dramatic therapeutic response within 3 months after GXNPC1® transplantation, where the NIHSS score improved by an average of 3.0 points in 3 month (8/9 subjects), and continued to improve to 2.7 points until 6 months (5/9 subjects).No serious adverse events (SUSAR) related to GXNPC1® were observed during the phase I and II clinical trials, indicating the safety of GXNPC1® transplantation.

Tzu Chi Da Ai Television's documentary "Guardians of Love as Healers: Reborn" (July 22, 2018)

Discovery Channel - "Taiwan's Incredible Showcase: Biomedical Technology" (October 19, 2020)

nstitute for Biotechnology and Medicine Industry (IBMI): A New Stem Cell Drug for Chronic Stroke – Syiyou | GWOXI Stem Cell Applied Technology (June 2, 2022)